1. Home
  2. OBK vs NTLA Comparison

OBK vs NTLA Comparison

Compare OBK & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBK
  • NTLA
  • Stock Information
  • Founded
  • OBK 1912
  • NTLA 2014
  • Country
  • OBK United States
  • NTLA United States
  • Employees
  • OBK N/A
  • NTLA N/A
  • Industry
  • OBK Major Banks
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • OBK Finance
  • NTLA Health Care
  • Exchange
  • OBK Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • OBK 1.2B
  • NTLA 1.2B
  • IPO Year
  • OBK 2018
  • NTLA 2016
  • Fundamental
  • Price
  • OBK $35.25
  • NTLA $11.57
  • Analyst Decision
  • OBK Buy
  • NTLA Buy
  • Analyst Count
  • OBK 7
  • NTLA 20
  • Target Price
  • OBK $43.00
  • NTLA $32.30
  • AVG Volume (30 Days)
  • OBK 152.1K
  • NTLA 3.9M
  • Earning Date
  • OBK 10-22-2025
  • NTLA 11-06-2025
  • Dividend Yield
  • OBK 1.69%
  • NTLA N/A
  • EPS Growth
  • OBK N/A
  • NTLA N/A
  • EPS
  • OBK 2.23
  • NTLA N/A
  • Revenue
  • OBK $340,866,000.00
  • NTLA $52,857,000.00
  • Revenue This Year
  • OBK $12.81
  • NTLA $8.32
  • Revenue Next Year
  • OBK $7.25
  • NTLA N/A
  • P/E Ratio
  • OBK $15.87
  • NTLA N/A
  • Revenue Growth
  • OBK N/A
  • NTLA 14.99
  • 52 Week Low
  • OBK $28.80
  • NTLA $5.90
  • 52 Week High
  • OBK $41.17
  • NTLA $23.76
  • Technical
  • Relative Strength Index (RSI)
  • OBK 33.65
  • NTLA 52.67
  • Support Level
  • OBK $34.72
  • NTLA $10.89
  • Resistance Level
  • OBK $39.06
  • NTLA $12.03
  • Average True Range (ATR)
  • OBK 0.84
  • NTLA 0.63
  • MACD
  • OBK -0.45
  • NTLA 0.01
  • Stochastic Oscillator
  • OBK 11.09
  • NTLA 43.49

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: